Verträglichkeit von Dienogest in der Endometriosetherapie: Analyse gepoolter Daten aus dem klinischen Entwicklungsprogramm

The paper pools data from four clinical development studies of dienogest 2 mg/day in 332 women with confirmed endometriosis, assessing adverse events, laboratory values, vital signs, body weight, and bleeding patterns over up to 65 weeks. It reports good overall tolerability with low rates of adverse events leading to discontinuation, with the most frequent adverse reactions being headache (9.0%), acne (5.1%), and nausea (4.2%). Unlike the GnRH agonist leuprorelin acetate, dienogest did not show relevant hypoestrogenism-related effects such as decreased mean bone mineral density or increased hot flushes, and it was described as metabolically neutral with minimal weight change. Relevance to endometriosis: This paper is centrally about endometriosis—pooled tolerability and adverse-effect characterization of dienogest used for endometriosis-associated pain.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works